161 related articles for article (PubMed ID: 38200580)
21. Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
Vollmer J; Ecker J; Hielscher T; Valinciute G; Ridinger J; Jamaladdin N; Peterziel H; van Tilburg CM; Oehme I; Witt O; Milde T
J Neurooncol; 2023 Sep; 164(3):617-632. PubMed ID: 37783879
[TBL] [Abstract][Full Text] [Related]
22. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.
Valinciute G; Ecker J; Selt F; Hielscher T; Sigaud R; Ridinger J; Thatikonda V; Gatzweiler C; Robinson S; Talbot J; Bernardi F; Picard D; Blattner-Johnson M; Schmid S; Jones DT; van Tilburg CM; Capper D; Kool M; Remke M; Oehme I; Pfister SM; Roussel MF; Ayrault O; Witt O; Milde T
J Neurooncol; 2023 May; 163(1):143-158. PubMed ID: 37183219
[TBL] [Abstract][Full Text] [Related]
23. OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
Xu Z; Murad N; Malawsky D; Tao R; Rivero-Hinojosa S; Holdhof D; Schüller U; Zhang P; Lazarski C; Rood BR; Packer R; Gershon T; Pei Y
Clin Cancer Res; 2022 Oct; 28(19):4278-4291. PubMed ID: 35736214
[TBL] [Abstract][Full Text] [Related]
24. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
[TBL] [Abstract][Full Text] [Related]
25. RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification.
Ćwiek P; Leni Z; Salm F; Dimitrova V; Styp-Rekowska B; Chiriano G; Carroll M; Höland K; Djonov V; Scapozza L; Guiry P; Arcaro A
Oncotarget; 2015 Jan; 6(1):116-29. PubMed ID: 25402633
[TBL] [Abstract][Full Text] [Related]
26. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
[TBL] [Abstract][Full Text] [Related]
27. c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients.
von Bueren AO; Oehler C; Shalaby T; von Hoff K; Pruschy M; Seifert B; Gerber NU; Warmuth-Metz M; Stearns D; Eberhart CG; Kortmann RD; Rutkowski S; Grotzer MA
BMC Cancer; 2011 Feb; 11():74. PubMed ID: 21324178
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
29. Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy.
Chaturvedi NK; Kling MJ; Coulter DW; McGuire TR; Ray S; Kesherwani V; Joshi SS; Sharp JG
Oncotarget; 2018 Mar; 9(24):16619-16633. PubMed ID: 29682173
[TBL] [Abstract][Full Text] [Related]
30. Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma.
Fiaschetti G; Castelletti D; Zoller S; Schramm A; Schroeder C; Nagaishi M; Stearns D; Mittelbronn M; Eggert A; Westermann F; Ohgaki H; Shalaby T; Pruschy M; Arcaro A; Grotzer MA
Oncogene; 2011 Jun; 30(25):2823-35. PubMed ID: 21317922
[TBL] [Abstract][Full Text] [Related]
31. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Weekes CD; Song D; Arcaroli J; Wilson LA; Rubio-Viqueira B; Cusatis G; Garrett-Mayer E; Messersmith WA; Winn RA; Hidalgo M
Neoplasia; 2012 Aug; 14(8):690-701. PubMed ID: 22952422
[TBL] [Abstract][Full Text] [Related]
32. Effective Inhibition of
Zhao Y; Li T; Tian S; Meng W; Sui Y; Yang J; Wang B; Liang Z; Zhao H; Han Y; Tang Y; Zhang L; Ma J
Cancer Manag Res; 2020; 12():12473-12485. PubMed ID: 33299354
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
[TBL] [Abstract][Full Text] [Related]
34. MiR-222-3p inhibits formation of medulloblastoma stem-like cells by targeting Notch2/c-myc signaling pathway.
Wang H; Wang Y; Wang Y
Immunopharmacol Immunotoxicol; 2022 Aug; 44(4):548-555. PubMed ID: 35379056
[TBL] [Abstract][Full Text] [Related]
35. Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma.
Shishido K; Purvis IJ; Velpula KK; Venkataraman S; Vibhakar R; Asuthkar S
Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114557
[TBL] [Abstract][Full Text] [Related]
36. Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma.
Kumar V; Wang Q; Sethi B; Lin F; Kumar V; Coulter DW; Dong Y; Mahato RI
Biomaterials; 2021 Nov; 278():121138. PubMed ID: 34634662
[TBL] [Abstract][Full Text] [Related]
37. Suppression of STAT3 NH
Ray S; Coulter DW; Gray SD; Sughroue JA; Roychoudhury S; McIntyre EM; Chaturvedi NK; Bhakat KK; Joshi SS; McGuire TR; Sharp JG
Mol Carcinog; 2018 Apr; 57(4):536-548. PubMed ID: 29280516
[TBL] [Abstract][Full Text] [Related]
38. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
39. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
[TBL] [Abstract][Full Text] [Related]
40. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma.
Bandopadhayay P; Piccioni F; O'Rourke R; Ho P; Gonzalez EM; Buchan G; Qian K; Gionet G; Girard E; Coxon M; Rees MG; Brenan L; Dubois F; Shapira O; Greenwald NF; Pages M; Balboni Iniguez A; Paolella BR; Meng A; Sinai C; Roti G; Dharia NV; Creech A; Tanenbaum B; Khadka P; Tracy A; Tiv HL; Hong AL; Coy S; Rashid R; Lin JR; Cowley GS; Lam FC; Goodale A; Lee Y; Schoolcraft K; Vazquez F; Hahn WC; Tsherniak A; Bradner JE; Yaffe MB; Milde T; Pfister SM; Qi J; Schenone M; Carr SA; Ligon KL; Kieran MW; Santagata S; Olson JM; Gokhale PC; Jaffe JD; Root DE; Stegmaier K; Johannessen CM; Beroukhim R
Nat Commun; 2019 Jun; 10(1):2400. PubMed ID: 31160565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
